Tempest Therapeutics Inc (TPST) — Cash Flow-to-Debt Ratio
Tempest Therapeutics Inc (TPST) has a Cash Flow-to-Debt Ratio of -0.35x as of December 2025, meaning its operating cash flow of $-3.57 Million could theoretically repay 0% of its total liabilities ($10.26 Million) in one year. See how much free cash does Tempest Therapeutics Inc generate to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Tempest Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Tempest Therapeutics Inc across 14 annual periods. Also explore net asset momentum of Tempest Therapeutics Inc to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Tempest Therapeutics Inc (2012–2025)
Year-by-year debt coverage analysis for Tempest Therapeutics Inc. For market capitalisation and broader financial context, see market value of Tempest Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.61x | $-26.82 Million | $10.26 Million | ▼ -76.9% |
| 2024 | -1.48x | $-33.03 Million | $22.36 Million | ▼ -34.1% |
| 2023 | -1.10x | $-27.36 Million | $24.84 Million | ▲ +0.8% |
| 2022 | -1.11x | $-31.07 Million | $27.98 Million | ▼ -58.8% |
| 2021 | -0.70x | $-25.96 Million | $37.12 Million | ▼ -237.0% |
| 2020 | -0.21x | $-19.02 Million | $91.66 Million | ▲ +92.4% |
| 2019 | -2.73x | $-41.22 Million | $15.10 Million | ▼ -26.4% |
| 2018 | -2.16x | $-23.65 Million | $10.95 Million | ▲ +48.7% |
| 2017 | -4.21x | $-20.34 Million | $4.83 Million | ▲ +2.3% |
| 2016 | -4.31x | $-61.73 Million | $14.32 Million | ▼ -0.8% |
| 2015 | -4.27x | $-50.29 Million | $11.76 Million | ▼ -43.2% |
| 2014 | -2.99x | $-30.59 Million | $10.25 Million | ▲ +3.6% |
| 2013 | -3.10x | $-18.09 Million | $5.84 Million | ▲ +41.9% |
| 2012 | -5.33x | $-11.16 Million | $2.09 Million | — |